December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Iganidipine, a Water-Soluble Ca2+ Channel Blocker, Partly Prevents Glutamate-Induced Neurotoxicity in Rat Retina
Author Affiliations & Notes
  • M Ohashi
    Ophthalmology Tokyo Metropolital Ger Medical C Tokyo Japan
  • S Saito
    Department of ophthalmology Kamifukuoka hospital Tokyo Japan
  • Y Suzuki
    Department of ophthalmology Tokyo university Tokyo Japan
  • M Araie
    Department of ophthalmology Tokyo university Tokyo Japan
  • K Kashiwagi
    Department of ophthalmology Yamanashi medical college Yamanashi Japan
  • Footnotes
    Commercial Relationships   M. Ohashi, None; S. Saito, None; Y. Suzuki, None; M. Araie, None; K. Kashiwagi, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2202. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M Ohashi, S Saito, Y Suzuki, M Araie, K Kashiwagi; Iganidipine, a Water-Soluble Ca2+ Channel Blocker, Partly Prevents Glutamate-Induced Neurotoxicity in Rat Retina . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2202.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Iganidipine is a water soluble Ca2+ channel blocker which can be prepared as ophthalmic solution. We have evaluated the neuroprotective effects of Iganidipine against glutamate receptors-mediated retinal damage in rat. Methods: NMDA (N-methyl-D-aspartic acid 200nmol) or KA(kainate acid 3nmol) was injected to vitreous of Male Sprague-Dawley rats to induce excitotoxic retinal ganglion cell (RGC) damage. The extent of RGC damage was evaluated by histological measurement of inner retinal cell layer thickness and by RGC counting with retrograde DiI labeling of RGCs. Iganidipine (6pmol,0.6pmol,o.06pmol) was injected with NMDA or KA intravitreously. As positive controls, MK801 (10nmol) or DNQX (6,7-dinitroquinoxaline-2,3-dione,0.125nmol) were injected intravitreously with NMDA or KA, respectively. The histlogical examination was performed seven days after the injection. For the RGC counting, DiI was injected into superior colliculi 5 days prior to the intravitreal injection of drugs for the retrograde labeling of RGCs and the number of labeled RGCs were counted microscopically 7 days after the injection. The other eye was used as control. Results: Intravitreal injection of NMDA reduced thickness of the inner plexiform layer (IPL) to 55±10% of control. Co-administration of MK801 with NMDA significantly prevented retinal damage (93±7% reduction) but iganidipine did not significantly prevent the NMDA-induced IPL thickness reduction. Intravitreal injection of KA reduced thickness of the inner plexiform layer (IPL) to 26±17% of control. Co-injection of 6pmol Iganidipine significantly prevented retinal damage (50±13 % reduction) along with co-administration of DNQX (93±7% reduction). Same results was seen in number of ganglion cells . Conclusion: Iganidipine partly prevents glutamate-induced neurotoxicity in rat retina .

Keywords: 489 neuroprotection • 334 calcium • 436 injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×